Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo(Kindai University), Yasuaki Arai(Tokyo National Hospital), Takuji Torimura(Omuta hospital), Takahiro Yamasaki(Yamaguchi University), Shunsuke Nojiri(Nagoya City University), Masafumi Ikeda(National Cancer Center Hospital East), Keisuke Hino(Yamaguchi University), Norihiro Kokudo(National Center for Global Health and Medicine), Teiji Kuzuya(Nagoya University), Kazuhiko Nakao(Nagasaki University), Hiroshi Aikata(Hiroshima Prefectural Hospital), Philip J. Johnson(Prince of Wales Hospital), Naoto Kawabe(Fujita Health University), Kenichi Yoshimura(Hiroshima University), Junji Furuse(Kanagawa Prefectural Hospital Organization), Hidetaka Tsumura(Hyogo Prefectural Cancer Center), Namiki Izumi(Musashino Red Cross Hospital), Takuji Okusaka(National Cancer Centre Japan), Kazuomi Ueshima(Kindai University), Yoshiyuki Wada(National Kyushu Medical Center), Osamu Yokosuka(Chiba University), Norio Isoda(Jichi Medical University), Kohichiroh Yasui(Kyoto Prefectural University of Medicine), Kiwamu Okita(Tokuyama (Japan)), Hajime Aino, Akio Ido(Kagoshima University), Nobukazu Tanabe(Sendai Medical Center)
Cited by 720
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977